arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Stuart Pocock

52 papers · 1975–2026

1975: 11976: 01977: 11978: 01979: 11980: 11981: 11982: 31983: 01984: 11985: 11986: 11987: 21988: 11989: 01990: 21991: 01992: 41993: 11994: 01995: 01996: 11997: 11998: 21999: 12000: 02001: 42002: 32003: 12004: 02005: 12006: 22007: 02008: 02009: 02010: 12011: 02012: 02013: 42014: 02015: 22016: 12017: 02018: 12019: 02020: 12021: 12022: 12023: 02024: 02025: 02026: 3
1975peak 4 in 19922026

Frequent co-authors

Papers

showing 1–25 of 52 RSS

Clinical Trials: A Practical Approach.

Ira Hill, Stuart Pocock

Statistics and Probability · Biometrics · · cited 2,961× · DOI ↗ · more like this ·

Introduction: The Rationale of Clinical Trials. The Historical Development of Clinical Trials. Organization and Planning. The Justificaton for Randomized Controlled Trials. Methods of Randomization. Blinding and Placebos. Ethical Issues. Crossover Trials. The Size of a Clinical Trial. Monitoring Trial Progress. Forms and Data Management. Protocol Deviations. Basic Principles of Statistical Analysis. Further Aspects of Data Analysis. Publication and Interpretation of Findings. References. Index.

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Stuart Pocock, Richard Simon

Statistics and Probability · Biometrics · · cited 2,364× · DOI ↗ · more like this ·

In controlled clinical trials there are usually several prognostic factors known or thought to influence the patient's ability to respond to treatment. Therefore, the method of sequential treatment assignment needs to be designed so that treatment balance is simultaneously achieved across all such patients factor. Traditional methods of restricted randomization such as "permuted blocks within strata" prove inadequate once the number of strata, or combinations of factor levels, approaches the sample size. A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor. The improved treatment balance obtained by this approach is explored using simulation for a simple model of a clinical trial. Further discussion centers on the selection, predictability…

Group sequential methods in the design and analysis of clinical trials

Stuart Pocock

Statistics and Probability · Biometrika · · cited 1,785× · DOI ↗ · more like this ·

In clinical trials with sequential patient entry, fixed sample size designs are unjustified on ethical grounds and sequential designs are often impracticable. One solution is a group sequential design dividing patient entry into a number of equal-sized groups so that the decision to stop the trial or continue is based on repeated significance tests of the accumulated data after each group is evaluated. Exact results are obtained for a trial with two treatments and a normal response with known variance. The design problem of determining the required size and number of groups is also considered. Simulation shows that these normal results may be adapted to other types of response data. An example shows that group sequential designs can sometimes be statistically superior to standard sequential designs.

Reporting of Noninferiority and Equivalence Randomized Trials

Gilda Piaggio, Diana R Elbourne, Douglas G. Altman +3 more

Statistics and Probability · JAMA · · cited 1,140× · DOI ↗ · more like this ·

The CONSORT (Consolidated Standards of Reporting Trials) Statement, including a checklist and a flow diagram, was developed to help authors improve their reporting of randomized controlled trials. Its primary focus was on individually randomized trials with 2 parallel groups that assess the possible superiority of one treatment compared with another but is now being extended to other trial designs. Noninferiority and equivalence trials have methodological features that differ from superiority trials and present particular difficulties in design, conduct, analysis, and interpretation. Although the rationale for such trials occurs frequently, those designed and described specifically as noninferiority or equivalence trials appear less commonly in the medical literature. The quality of reporting of those that are published is often inadequate. In this article, we present an adapted CONSORT…

Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems

Stuart Pocock, Susan E. Assmann, Laura E. Enos +1 more

Statistics and Probability · Statistics in Medicine · · cited 1,090× · DOI ↗ · more like this ·

Clinical trial investigators often record a great deal of baseline data on each patient at randomization. When reporting the trial's findings such baseline data can be used for (i) subgroup analyses which explore whether there is evidence that the treatment difference depends on certain patient characteristics, (ii) covariate-adjusted analyses which aim to refine the analysis of the overall treatment difference by taking account of the fact that some baseline characteristics are related to outcome and may be unbalanced between treatment groups, and (iii) baseline comparisons which compare the baseline characteristics of patients in each treatment group for any possible (unlucky) differences. This paper examines how these issues are currently tackled in the medical journals, based on a recent survey of 50 trial reports in four major journals. The statistical ramifications are explored…

Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design

Lars Frison, Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 605× · DOI ↗ · more like this ·

This paper explores the use of simple summary statistics for analysing repeated measurements in randomized clinical trials with two treatments. Quite often the data for each patient may be effectively summarized by a pre-treatment mean and a post-treatment mean. Analysis of covariance is the method of choice and its superiority over analysis of post-treatment means or analysis of mean changes is quantified, as regards both reduced variance and avoidance of bias, using a simple model for the covariance structure between time points. Quantitative consideration is also given to practical issues in the design of repeated measures studies: the merits of having more than one pre-treatment measurement are demonstrated, and methods for determining sample sizes in repeated measures designs are provided. Several examples from clinical trials are presented, and broad practical recommendations are…

The Analysis of Multiple Endpoints in Clinical Trials

Stuart J. Pocock, Nancy L. Geller, Anastasios A. Tsiatis

Statistics and Probability · Biometrics · · cited 530× · DOI ↗ · more like this ·

Treatment comparisons in randomized clinical trials usually involve several endpoints such that conventional significance testing can seriously inflate the overall Type I error rate. One option is to select a single primary endpoint for formal statistical inference, but this is not always feasible. Another approach is to apply Bonferroni correction (i.e., multiply each P-value by the total number of endpoints). Its conservatism for correlated endpoints is examined for multivariate normal data. A third approach is to derive an appropriate global test statistic and this paper explores one such test applicable to any set of asymptotically normal test statistics. Quantitative, binary, and survival endpoints are all considered within this general framework. Two examples are presented and the relative merits of the proposed strategies are discussed.

Adaptive increase in sample size when interim results are promising: A practical guide with examples

Cyrus R. Mehta, Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 362× · DOI ↗ · more like this ·

This paper discusses the benefits and limitations of adaptive sample size re-estimation for phase 3 confirmatory clinical trials. Comparisons are made with more traditional fixed sample and group sequential designs. It is seen that the real benefit of the adaptive approach arises through the ability to invest sample size resources into the trial in stages. The trial starts with a small up-front sample size commitment. Additional sample size resources are committed to the trial only if promising results are obtained at an interim analysis. This strategy is shown through examples of actual trials, one in neurology and one in cardiology, to be more advantageous than the fixed sample or group sequential approaches in certain settings. A major factor that has generated controversy and inhibited more widespread use of these methods has been their reliance on non-standard tests and p-values…

Interim Analyses for Randomized Clinical Trials: The Group Sequential Approach

Stuart Pocock

Statistics and Probability · Biometrics · · cited 265× · DOI ↗ · more like this ·

For many clinical trials interim analyses are undertaken periodically, one purpose being to determine whether to stop the trial early because of a substantial treatment difference. There exist group sequential designs for such trials, on simple approach being to decide in advance on a maximum number of analyses and then to apply repeated significance tests to the accumulating data. To allow for repeated testing one uses a more stringent (nominal) significance level as a stopping rule. Power calculations based on results for normal group sequential designs obtained by numerical integration, enable one to determine the number of patients to be evaluated between analyses. There appears to be little advantage in analysing trial data on more than five occasions unless one anticipates the possibility of an extremely large treatment difference. As an alternative to having a constant nominal…

When to stop a clinical trial.

Stuart Pocock

Statistics and Probability · BMJ · · cited 256× · DOI ↗ · more like this ·

Most randomised clinical trials require periodic monitoring of the accumulating data. While the efficiency of trial management is enhanced by data monitoring, ethical reasons should primarily dictate the need to terminate or change a trial in response to interim findings.

Allocation of Patients to Treatment in Clinical Trials

Stuart Pocock

Statistics and Probability · Biometrics · · cited 249× · DOI ↗ · more like this ·

This article is intended as a practical guide to the various methods of patient assignment in clinical trials. Topics discussed include a critical appraisal of non-randomized studies, methods of restricted randomization such as random permuted blocks and the biased coin technique, the extent to which stratification is necessary and the methods available, the possible benefits of randomization with a greater proportion of patients on a new treatment, factorial designs, crossover designs, randomized consent designs and adaptive assignment procedures. With all this diversity of approach it needs to be remembered that the effective implementation and reliability of a relatively straightforward randomization scheme may be more important than attempting theoretical optimality with more complex designs.

The win ratio approach for composite endpoints: practical guidance based on previous experience

Björn Redfors, John Gregson, Aaron Crowley +4 more

Statistics and Probability · European Heart Journal · · cited 201× · DOI ↗ · more like this ·

The win ratio was introduced in 2012 as a new method for examining composite endpoints and has since been widely adopted in cardiovascular (CV) trials. Improving upon conventional methods for analysing composite endpoints, the win ratio accounts for relative priorities of the components and allows the components to be different types of outcomes. For example, the win ratio can combine the time to death with the number of occurrences of a non-fatal outcome such as CV-related hospitalizations (CVHs) in a single hierarchical composite endpoint. The win ratio can provide greater statistical power to detect and quantify a treatment difference by using all available information contained in the component outcomes. The win ratio can also incorporate quantitative outcomes such as exercise tests or quality-of-life scores. There is a need for more practical guidance on how best to design trials…

Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners

Nancy L. Geller, Stuart Pocock

Statistics and Probability · Biometrics · · cited 201× · DOI ↗ · more like this ·

Recent developments in group sequential methods have had a great impact on the design and analysis of randomized clinical trials. The consequences for both planned and unplanned interim analyses are discussed using several real trials as illustrations. Guidelines for the conduct of interim analysis are given, including tables of nominal significance levels and required sample sizes for several group sequential plans. Areas in need of further theoretical advance include multiple endpoints, estimation of treatment differences, stratification, and design of multiple-armed trials.

Regression of Area Mortality Rates on Explanatory Variables: What Weighting is Appropriate?

Stuart Pocock, Derek G. Cook, Shirley A.A. Beresford

Statistics and Probability · Journal of the Royal Statistical Society Series C (Applied Statistics) · · cited 162× · DOI ↗ · more like this ·

"One can often gain insight into the aetiology of a disease by relating mortality rates in different areas to explanatory variables. Multiple regression techniques are usually employed, but unweighted least squares may be inappropriate if the areas vary in population size. Also, a fully weighted regression, with weights inversely proportional to binomial sampling variances, is usually too extreme. This paper proposes an intermediate solution via maximum likelihood which takes account of three sources of variation in death rates: sampling error, explanatory variables and unexplained differences between areas. The method is also adapted for logit (death rates), standardized mortality ratios (SMRs) and log (SMRs). Two [United Kingdom] examples are presented."

British Regional Heart Study: geographic variations in cardiovascular mortality, and the role of water quality

Stuart Pocock, A. G. Shaper, Derek G. Cook +4 more

Health · BMJ · · cited 157× · DOI ↗ · more like this ·

In a study of regional variations in cardiovascular mortality in Great Britain during 1969-73 based on 253 towns the possible contributions of drinking water quality, climate, air pollution, blood groups, and socioeconomic factors were evaluated. A twofold range in mortality from stroke and ischaemic heart disease was apparent, the highest mortality being in the west of Scotland and the lowest in south-east England. A multifactorial approach identified five principal factors that substantially explained this geographic variation in cardiovascular mortality-namely, water hardness, rainfall, temperature, and two social factors (percentage of manual workers and car ownership). After adjustment for other factors cardiovascular mortality in areas with very soft water, around 0.25 mmol/l (calcium carbonate equivalent 25 mg/l), was estimated to be 10-15% higher than that in areas with…

Stopping rules and estimation problems in clinical trials

Michael D. Hughes, Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 129× · DOI ↗ · more like this ·

Stopping rules in clinical trials can lead to bias in point estimation of the magnitude of treatment difference. A simulation exercise, based on estimation of the risk ratio in a typical post-myocardial infarction trial, examines the nature of this exaggeration of treatment effect under various group sequential plans and also under continuous naive monitoring for statistical significance. For a fixed treatment effect the median bias in group sequential design is small, but it is greatest for effects that the trial has reasonable power to detect. Bias is evidently greater in trials that stop early and is dramatic under naive monitoring for significance. Group sequential plans lead to a multimodal sampling distribution of treatment effect, which poses problems for incorporating their estimates into meta-analyses. By simulating a population of trials with treatment effects modelled by an…

Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials

Brian Claggett, Stuart Pocock, Lee‐Jen Wei +3 more

Statistics and Probability · Circulation · · cited 113× · DOI ↗ · more like this ·

BACKGROUND: Most phase-3 trials feature time-to-first event end points for their primary and secondary analyses. In chronic diseases, where a clinical event can occur >1 time, recurrent-event methods have been proposed to more fully capture disease burden and have been assumed to improve statistical precision and power compared with conventional time-to-first methods. METHODS: To better characterize factors that influence statistical properties of recurrent-event and time-to-first methods in the evaluation of randomized therapy, we repeatedly simulated trials with 1:1 randomization of 4000 patients to active versus control therapy, with true patient-level risk reduction of 20% (ie, relative risk=0.80). For patients who discontinued active therapy after a first event, we assumed their risk reverted subsequently to their original placebo-level risk. Through simulation, we varied the…

The pros and cons of noninferiority trials

Stuart Pocock

Statistics and Probability · Fundamental and Clinical Pharmacology · · cited 111× · DOI ↗ · more like this ·

Noninferiority trials comparing new treatment with an active standard control are becoming increasingly common. This article discusses relevant issues regarding their need, design, analysis and interpretation: the appropriate choice of control group, types of noninferiority trial, ethical considerations, sample size determination and potential pitfalls to consider.

Current issues in the design and interpretation of clinical trials.

Stuart Pocock

Statistics and Probability · BMJ · · cited 97× · DOI ↗ · more like this ·

Though there have been considerable improvements in the use of statistical methods for clinical trials in recent years, there remain major practical difficulties in the design and interpretation of many trials. This paper concentrates on problems relating to randomisation, the overemphasis on significance testing, and the inadequate size of many trials. Each topic is illustrated by examples from recent trials.

Coping with missing data in clinical trials: A model‐based approach applied to asthma trials

James R. Carpenter, Stuart Pocock, Carl Johan Lamm

Statistics and Probability · Statistics in Medicine · · cited 90× · DOI ↗ · more like this ·

In most clinical trials, some patients do not complete their intended follow-up according to protocol, for a variety of reasons, and are often described as having 'dropped out' before the conclusion of the trial. Their subsequent measurements are missing, and this makes the analysis of the trial's repeated measures data more difficult. In this paper we briefly review the reasons for patient drop-out, and their implications for some commonly used methods of analysis. We then propose a class of models for modelling both the response to treatment and the drop-out process. Such models are readily fitted in a Bayesian framework using non-informative priors with the software BUGS. The results from such models are then compared with the results of standard methods for dealing with missing data in clinical trials, such as last observation carried forward. We further propose the use of a time…

Current controversies in data monitoring for clinical trials

Stuart Pocock

Statistics and Probability · Clinical Trials · · cited 82× · DOI ↗ · more like this ·

This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensible statistical boundary for stopping a trial early for benefit, bearing in mind that one usually needs proof beyond reasonable doubt of a treatment benefit sufficient to alter future clinical practice. Appropriate choices of stopping boundary for harm and futility are also discussed. The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule.

Socioeconomic Deprivation: An Important, Largely Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease

Dorien M Kimenai, Leah Pirondini, John Gregson +9 more

Health · Circulation · · cited 76× · DOI ↗ · more like this ·

Background: Socioeconomic deprivation is associated with higher cardiovascular morbidity and mortality. Whether deprivation status should be incorporated in more cardiovascular risk estimation scores remains unclear. This study evaluates how socioeconomic deprivation status affects the performance of 3 primary prevention cardiovascular risk scores. Methods: The Generation Scotland Scottish Family Health Study was used to evaluate the performance of 3 cardiovascular risk scores with (ASSIGN [Assessing cardiovascular risk using SIGN (Scottish Intercollegiate Guidelines Network) guidelines to ASSIGN preventive treatment]) and without (SCORE2 [Systematic Coronary Risk Evaluation 2 algorithm], Pooled Cohort Equations) socioeconomic deprivation as a covariate in the risk prediction model. Deprivation was defined by Scottish Index of Multiple Deprivation score. The predicted 10-year risk was…

Statistical and ethical issues in monitoring clinical trials

Stuart Pocock

Statistics and Probability · Statistics in Medicine · · cited 76× · DOI ↗ · more like this ·

Abstract Most randomized clinical trials require periodic monitoring of the accumulating data. While the efficiency of trial management is enhanced by data monitoring, ethical reasons should primarily dictate the need to terminate or change a trial in response to interim findings. This article focuses on the ethical dilemma of when to stop a clinical trial and places statistical stopping rules in the context of such ethical decision making. Other issues include the organization of data monitoring committees and the problems of premature publication and exaggerated estimation in trials that stop early. Several topical examples are used to convey the relevance of these issues to current practice.

Statistical Aspects of Clinical Trial Design

Stuart Pocock

Statistics and Probability · Journal of the Royal Statistical Society Series D (The Statistician) · · cited 76× · DOI ↗ · more like this ·

Stuart J. Pocock, Statistical Aspects of Clinical Trial Design, Journal of the Royal Statistical Society. Series D (The Statistician), Vol. 31, No. 1, Proceedings of the 1981 I.O.S. Annual Conference on Statistics in Medicine (Mar., 1982), pp. 1-18

A win ratio approach to comparing continuous non‐normal outcomes in clinical trials

Duolao Wang, Stuart Pocock

Statistics and Probability · Pharmaceutical Statistics · · cited 74× · DOI ↗ · more like this ·

Clinical trials are often designed to compare continuous non-normal outcomes. The conventional statistical method for such a comparison is a non-parametric Mann-Whitney test, which provides a P-value for testing the hypothesis that the distributions of both treatment groups are identical, but does not provide a simple and straightforward estimate of treatment effect. For that, Hodges and Lehmann proposed estimating the shift parameter between two populations and its confidence interval (CI). However, such a shift parameter does not have a straightforward interpretation, and its CI contains zero in some cases when Mann-Whitney test produces a significant result. To overcome the aforementioned problems, we introduce the use of the win ratio for analysing such data. Patients in the new and control treatment are formed into all possible pairs. For each pair, the new treatment patient is…